SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a record number of optical genome mapping (OGM) presentations scheduled to appear at the annual Cancer Genomics Consortium (CGC) meeting being held from August 1 - 4, 2021. Across this four-day event, the meeting features 10 presentations by Bionano’s Saphyr® customers highlighting the benefits of OGM for clinical research applications in solid tumor analysis, hematological malignancies, products of conception, prenatal and postnatal constitutional genetics.
In 2020, more than 500 participants from around the globe attended the CGC’s virtual meeting and attendance for this year’s four-day event is anticipated to be even higher. The 10 upcoming presentations featuring Saphyr-generated OGM data are listed below along with the associated application areas:
|OGM Application Area||Presenter||Affiliation||Presentation Title|
|Solid Tumor Analysis||Dr. Miriam Bornhorst||Children's National Hospital||Optical genome mapping reveals novel structural variants in pediatric high grade gliomas.|
|Dr. Nikhil Sahajpal||Augusta University||Clinical utility and feasibility of adopting optical genome mapping for chromosomal characterization of solid tumors.|
|Hematological Malignancies||Dr. Rashmi Kanagal-Shamanna||MD Anderson Cancer Center||Optical genome mapping for chromosomal structural variants analysis in hematological malignancies.|
|Dr. Gordana Raca||Children's Hospital Los Angeles||Complementarity of RNA sequencing and optical genome mapping in detection of rare fusions in pediatric B-ALL.|
|Dr. Victoria Stinnett||The Johns Hopkins University||Adoption of optical genome mapping in clinical cancer cytogenetic laboratory: A stepwise approach.|
|Dr. Guilin Tang||UT MD Anderson Cancer Center||Optical Genome Mapping Reveals Genomic Complexity and Detects Novel Genetic Abnormalities in T-Lymphoblastic Leukemia.|
|Dr. Jia-Chi Wang||City of Hope National Medical Center||Integrative cytogenomics studies using optical genome mapping in two cases with chronic lymphocytic leukemia.|
|Prenatal Genetics||Nikhil Sahajpal||Augusta University||Next-generation cytogenetics: Proposal for a cost-effective approach for comprehensive testing of prenatal cases.|
|Products of Conception||Dr. Nikhil Sahajpal||Augusta University||Optical genome mapping and SNP microarray: integrated workflow for optimizing analysis of products of conception.|
|Postnatal/Constitutional Genetics||Dr. Thuy Phung||University of South Alabama||Genomic structural variations in lymphatic anomalies.|
“We are thrilled to see the broad adoption of OGM by members of the CGC community of clinical researchers, who have rigorously compared the performance of OGM to the standard of care methods, such as, Karyotyping, FISH and other targeted tests,” said Alka Chaubey, PhD, Chief Medical Officer of Bionano Genomics. “In all the presentations, there are recurring themes of increased sensitivity, higher success rates and an easier workflow using OGM for the detection of clinically relevant structural variations in prenatal, postnatal/constitutional genetics, blood cancers and solid tumor applications.”
In addition, Dr. Alka Chaubey will be presenting at the CGC meeting on August 2nd and leading a panel discussion on how OGM has the potential to usher in a new era for cancer genomics.
“This year’s CGC meeting has the greatest number of presentations featuring Bionano data to date,” commented Erik Holmlin, PhD, CEO of Bionano Genomics. “We believe this multitude of presentations shows how significant Bionano’s presence and that of OGM has become in the cancer research community. The progress we are seeing here within the US market, with all this OGM data being presented at the CGC meeting, is extremely encouraging and further reinforces our belief in the value proposition of our solution.”
For more details and to register for this online event please go to https://cancergenomics.org/meetings/cgc_annual_meeting.php
About Bionano Genomics
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: OGM’s potential transformative impact for cancer genomics; and adoption of OGM in the United States. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: potential inaccuracies in presentations given at the CGC meeting or subsequently published data that may minimize the impact of OGM in cancer genomics; the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2020 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
Investor Relations and
+1 (858) 366-3243